Sawicka-Gutaj, N.; Komarowska, H.; Gruszczyński, D.; Derwich, A.; Klimont, A.; Ruchała, M.
Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors. J. Clin. Med. 2022, 11, 5563.
https://doi.org/10.3390/jcm11195563
AMA Style
Sawicka-Gutaj N, Komarowska H, Gruszczyński D, Derwich A, Klimont A, Ruchała M.
Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors. Journal of Clinical Medicine. 2022; 11(19):5563.
https://doi.org/10.3390/jcm11195563
Chicago/Turabian Style
Sawicka-Gutaj, Nadia, Hanna Komarowska, Dawid Gruszczyński, Aleksandra Derwich, Anna Klimont, and Marek Ruchała.
2022. "Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors" Journal of Clinical Medicine 11, no. 19: 5563.
https://doi.org/10.3390/jcm11195563
APA Style
Sawicka-Gutaj, N., Komarowska, H., Gruszczyński, D., Derwich, A., Klimont, A., & Ruchała, M.
(2022). Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors. Journal of Clinical Medicine, 11(19), 5563.
https://doi.org/10.3390/jcm11195563